MalayalamNewsableKannadaKannadaPrabhaTeluguTamilBanglaHindiMarathiMyNation
Add Preferred SourceGoogle-icon
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Latest News
  • India
  • World
  • Business
  • Markets
  • Sports
  • Entertainment
  • Lifestyle
  • Creator Connect
  • IPL 2026
  • Home
  • World
  • Coronavirus: Widespread COVID-19 vaccinations not expected till mid-2021, says WHO expert

Coronavirus: Widespread COVID-19 vaccinations not expected till mid-2021, says WHO expert

 A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work 

2 Min read
Author : Team Asianet Newsable
Published : Sep 04 2020, 04:38 PM IST
Share this Photo Gallery
  • FB
  • TW
  • Linkdin
  • Whatsapp
  • GNFollow Us
17
<p style="text align: justify;">A World Health Organisation spokeswoman said on Friday it does not expect widespread vaccinations against COVID 19 until the middle of next year, stressing the importance of rigorous checks on their effectiveness and safety.<br />&nbsp;</p>

<p style="text-align: justify;">A World Health Organisation spokeswoman said on Friday it does not expect widespread vaccinations against COVID-19 until the middle of next year, stressing the importance of rigorous checks on their effectiveness and safety.<br />&nbsp;</p>

A World Health Organisation spokeswoman said on Friday it does not expect widespread vaccinations against COVID-19 until the middle of next year, stressing the importance of rigorous checks on their effectiveness and safety.
 

Add Asianet Newsable as a Preferred SourcegooglePreferred
27
<p>“We are not expecting to see widespread vaccination until the middle of next year”, spokeswoman Margaret Harris told journalists at a briefing in Geneva.<br />&nbsp;</p>

<p>“We are not expecting to see widespread vaccination until the middle of next year”, spokeswoman Margaret Harris told journalists at a briefing in Geneva.<br />&nbsp;</p>

“We are not expecting to see widespread vaccination until the middle of next year”, spokeswoman Margaret Harris told journalists at a briefing in Geneva.
 

37
<p>“This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is”, she added referring to vaccine clinical trials.<br />&nbsp;</p>

<p>“This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is”, she added referring to vaccine clinical trials.<br />&nbsp;</p>

“This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is”, she added referring to vaccine clinical trials.
 

47
<p>A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work.<br />&nbsp;</p>

<p>A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work.<br />&nbsp;</p>

A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work.
 

57
<p>The AstraZeneca shot is one of the leaders in the race to develop COVID-19 vaccine. AstraZeneca announced its vaccine candidate has entered the final testing stage in the US.<br />&nbsp;</p>

<p>The AstraZeneca shot is one of the leaders in the race to develop COVID-19 vaccine. AstraZeneca announced its vaccine candidate has entered the final testing stage in the US.<br />&nbsp;</p>

The AstraZeneca shot is one of the leaders in the race to develop COVID-19 vaccine. AstraZeneca announced its vaccine candidate has entered the final testing stage in the US.
 

67
<p style="text-align: justify;">The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.<br />&nbsp;</p>

<p style="text-align: justify;">The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.<br />&nbsp;</p>

The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.
 

77
<p>Two other vaccine candidates began final testing this summer in tens of thousands of people in the US. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germany's BioNTech.</p>

<p>Two other vaccine candidates began final testing this summer in tens of thousands of people in the US. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germany's BioNTech.</p>

Two other vaccine candidates began final testing this summer in tens of thousands of people in the US. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germany's BioNTech.

Check the Breaking News Today and Latest News from across India and around the world. Stay updated with the latest World News and global developments from politics to economy and current affairs. Get in-depth coverage of China News, Europe News, Pakistan News, and South Asia News, along with top headlines from the UK and US. Follow expert analysis, international trends, and breaking updates from around the globe. Download the Asianet News Official App from the Android Play Store and iPhone App Store for accurate and timely news updates anytime, anywhere.

 

About the Author

TA
Team Asianet Newsable
Team Asianet Newsable is the official profile used for publishing syndicated news agency stories on Asianet Newsable. This profile ensures accurate, credible, and timely reporting of national and international news across various categories, including politics, sports, entertainment, lifestyle, and more. Team Asianet Newsable curates and adapts wire service content to suit the platform’s diverse, multilingual audience, maintaining journalistic integrity and delivering fact-based news.

Latest Videos
Recommended Stories
Recommended image1
India, South Korea discuss defence industry, maritime security ties
Recommended image2
PM Modi's first bilateral Italy visit critical for ties, says MEA
Recommended image3
PM Modi's Italy visit: MoUs signed, ties now a Special Partnership
Recommended image4
India-Italy 'strategic partnership' to boost investments, culture
Recommended image5
India-UAE CEPA: Bilateral trade hits $101B, targets $200B by 2032
News
Breaking News TodayLatest News TodayIndia NewsWorld NewsKarnataka NewsKerala NewsIndian Defence NewsBengaluru News
Entertainment
Entertainment NewsOTT ReleaseBigg BossMovie ReviewsBox Office Collection
Sports
Sports NewsCricket NewsFootball NewsWWE NewsOther Sports
Lifestyle
Lifestyle NewsFood and RecipesHealth NewsAstrologyCareer NewsWeb Stories
Business
Business newsShare Market NewsGold PriceDA Hike8th Pay CommissionTechnology NewsAutomobile News
Weather
WeatherKolkata WeatherChennai WeatherBengaluru Weather
Asianet
Follow us on
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Download on Android
  • Download on IOS
  • About Website
  • Terms of Use
  • Privacy Policy
  • CSAM Policy
  • Complaint Redressal - Website
  • Compliance Report Digital
  • Investors
© Copyright 2026 Asianxt Digital Technologies Private Limited (Formerly known as Asianet News Media & Entertainment Private Limited) | All Rights Reserved